Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites.
Brown AJ, Precious HM, Whitcomb JM, Wong JK, Quigg M, Huang W, Daar ES, D'Aquila RT, Keiser PH, Connick E, Hellmann NS, Petropoulos CJ, Richman DD, Little SJ. Brown AJ, et al. Among authors: keiser ph. J Virol. 2000 Nov;74(22):10269-73. doi: 10.1128/jvi.74.22.10269-10273.2000. J Virol. 2000. PMID: 11044070 Free PMC article.
The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.
Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, Leedom J, Leibowitz M, Whitcomb JM, Richman D, McCutchan JA; California Collaborative Treatment Group. Haubrich RH, et al. Among authors: keiser ph. AIDS. 2002 Oct 18;16(15):F33-40. doi: 10.1097/00002030-200210180-00001. AIDS. 2002. PMID: 12370520 Clinical Trial.
Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.
Kemper CA, Witt MD, Keiser PH, Dubé MP, Forthal DN, Leibowitz M, Smith DS, Rigby A, Hellmann NS, Lie YS, Leedom J, Richman D, McCutchan JA, Haubrich R; California Collaborative Treatment Group #575 Team. Kemper CA, et al. Among authors: keiser ph. AIDS. 2001 Mar 30;15(5):609-15. doi: 10.1097/00002030-200103300-00010. AIDS. 2001. PMID: 11316998
Class-sparing regimens for initial treatment of HIV-1 infection.
Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW; AIDS Clinical Trials Group Study A5142 Team. Riddler SA, et al. N Engl J Med. 2008 May 15;358(20):2095-106. doi: 10.1056/NEJMoa074609. N Engl J Med. 2008. PMID: 18480202 Free PMC article. Clinical Trial.
Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase.
Brehm JH, Lalama CM, Hughes MD, Haubrich R, Riddler SA, Sluis-Cremer N, Mellors JW; AIDS Clinical Trials Group Study A5142 Protocol Team. Brehm JH, et al. J Acquir Immune Defic Syndr. 2011 Apr;56(4):344-8. doi: 10.1097/QAI.0b013e31820cf029. J Acquir Immune Defic Syndr. 2011. PMID: 21350368 Free PMC article.
Changes in thymic function with age and during the treatment of HIV infection.
Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, Polis MA, Haase AT, Feinberg MB, Sullivan JL, Jamieson BD, Zack JA, Picker LJ, Koup RA. Douek DC, et al. Among authors: keiser ph. Nature. 1998 Dec 17;396(6712):690-5. doi: 10.1038/25374. Nature. 1998. PMID: 9872319
76 results